Addus HomeCare (ADUS) director sells 250 common shares in open market
Addus HomeCare (ADUS) director Esteban Lopez reported an open-market sale of 250 common shares at a price of $93.00 per share on May 19, 2026. Following this transaction, Lopez directly holds 3,450 shares of Addus HomeCare common stock. The sale, valued at $23,250, was detailed in a Form 4 SEC filing.
Addus HomeCare Pursues Personal Care M&A As Shares Trade Below Targets
Addus HomeCare is actively pursuing mergers and acquisitions in personal care services, leveraging a strong balance sheet to target growth avenues outside federal moratoriums on certain home health licenses. The company's shares are currently trading below analyst targets and Simply Wall St's fair value estimate, reflecting recent share price pressure despite operational improvements and strategic M&A focus. Investors are advised to monitor acquisition details, personal care revenue mix, and the impact of technology on caregiver utilization and margins, while acknowledging execution risk.
Addus HomeCare Pursues Personal Care M&A As Shares Trade Below Targets
Addus HomeCare is focusing on personal care services expansion through mergers and acquisitions, supported by a strong balance sheet and limited impact from federal moratoriums. Despite recent share price pressure, the company is undervalued according to Simply Wall St, trading 30% below analyst targets. Key considerations for investors include monitoring acquisition execution, personal care revenue mix, and the effect of technology investments on caregiver utilization and margins.
Moratorium unlikely to hurt Addus’ M and A efforts, CEO Allison says
Dirk Allison, CEO of Addus HomeCare, stated that a new six-month Medicare enrollment moratorium for hospices and home care agencies is unlikely to affect Addus's operations or its merger and acquisition strategy. This is primarily because personal care services, which constitute the majority of Addus's business, are exempt from the moratorium. Allison also believes the government's crackdown on fraud might benefit large, compliant providers like Addus, potentially encouraging smaller agencies to sell.
Addus CEO: Moratorium Has Little To No Impact On Growth, Valuations
Addus HomeCare Corporation's CEO, Dirk Allison, stated that the recently announced moratorium on home health Medicare enrollment will have little to no impact on the company's growth strategy or valuations. This is because the moratorium primarily affects de novo companies, whereas Addus focuses on M&A and organic growth and its personal care services segment is not affected. Allison also noted that the company is actively pursuing acquisitions, including large ones comparable to its $350 million acquisition of Gentiva’s personal care assets.
ADUS Reiterated by Citizens -- Price Target Maintained at $142
Citizens has reiterated a "Market Outperform" rating for Addus HomeCare (ADUS), maintaining its price target at $142.00, despite mixed signals from other analysts. GuruFocus indicates ADUS is currently undervalued with a GF Value™ of $122.66 against a current price of $91.05, and boasts a strong GF Score™ of 93/100 suggesting potential for long-term returns. The company specializes in in-home care services, benefiting from an aging population.
Addus HomeCare Price Target Maintained With a $142.00/Share by Citizens
Citizens has maintained its price target for Addus HomeCare (NASDAQ: ADUS) at $142.00 per share. This indicates a consistent outlook on the company's valuation from the firm.
Citizens reiterates Addus HomeCare stock rating on valuation discount
Citizens has reaffirmed its "Market Outperform" rating and a $142.00 price target for Addus HomeCare (NASDAQ:ADUS), citing a significant valuation discount. The company's stock trades at 8.5x its 2026 EBITDA estimate, considerably below its five-year average, despite strong projected EBITDA growth and favorable regulatory conditions. This reiteration comes after mixed Q1 2026 results, where Addus HomeCare exceeded EPS expectations but missed on revenue.
Citizens reiterates Addus HomeCare stock rating on valuation discount By Investing.com
Citizens has reaffirmed its Market Outperform rating and $142.00 price target for Addus HomeCare (NASDAQ:ADUS), citing a valuation discount. The stock trades at 8.5x its 2026 EBITDA estimate, significantly below its five-year average of 13.4x, despite a projected 15% CAGR for EBITDA from 2021 to 2026. This valuation is seen as not fully reflecting potential upsides from M&A, improved census dynamics, and favorable regulatory conditions, even after a recent revenue miss in Q1 2026.
Addus HomeCare Corporation 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:ADUS) 2026-05-17
Addus HomeCare Corporation (ADUS) has published its slide deck in conjunction with its Q1 2026 earnings call. This presentation provides details related to the company's financial results and operational performance for the quarter ended May 17, 2026. The information is made available to investors and followers of the company on Seeking Alpha.
Addus HomeCare Corp stock (US0067391062): Solid Q1 2026 growth keeps healthcare services in focus
Addus HomeCare Corp reported strong Q1 2026 revenue and earnings growth, driven by continued demand for home-based care and successful integration of acquisitions. The company's business model focuses on personal care, home health, and hospice services, capitalizing on an aging population and the shift towards lower-cost care settings. Investors should monitor state-level funding decisions, operational execution, staffing, and regulatory changes, as these factors significantly influence the company's profitability and growth.
GoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo Shares Plummet, What You Need To Know
Shares of several healthcare-related companies, including GoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo, experienced a decline following the April PPI report showing accelerating wholesale inflation. The report indicated a 6% annual inflation rate and the fastest rise in service-sector prices in four years, creating a dual challenge for the healthcare industry through increased operating costs and potential regulatory intervention due to visible price-setting power. Among the impacted stocks, Addus HomeCare's shares fell 3.2%, adding to a year-to-date decline of 11.2%, with a previous drop attributed to a revenue miss in its first-quarter financial results.
Addus HomeCare Corporation (NASDAQ:ADUS) Receives Average Rating of "Moderate Buy" from Analysts
Addus HomeCare Corporation (NASDAQ:ADUS) has received a "Moderate Buy" consensus rating from 11 analysts, with an average 12-month price target of $131.22. The company recently exceeded Q1 earnings estimates with $1.62 per share and saw revenue increase by 7.7% to $363.5 million. Despite some insider selling, institutional investors hold a significant 95.35% stake in the company.
Addus HomeCare Corp stock (US0067391062): 52-week low tests investor patience despite solid earnings
Addus HomeCare Corp (ADUS) stock recently hit a 52-week low near 90 USD despite reporting higher first-quarter revenue and earnings. This disconnect between operational performance and market sentiment is attributed to investor caution regarding reimbursement trends, labor costs, and broader sector rotations. Despite the stock's weakness, analysts maintain a "Moderate Buy" consensus with an average 12-month price target significantly above the current price.
Addus HomeCare stock hits 52-week low at $90.80 By Investing.com
Addus HomeCare Corporation's stock has dropped to a 52-week low of $90.80, marking a 16% decrease over the past year. Despite a "GREAT" financial health score and earnings per share beating analyst expectations, revenue for Q1 2026 fell short, leading Citizens to lower its price target. InvestingPro analysis suggests the stock may be undervalued given its P/E and PEG ratios.
GoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo Shares Plummet, What You Need To Know
Shares of several healthcare and life sciences companies, including GoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo, declined after an April PPI report indicated accelerating wholesale inflation, particularly in the service sector. This inflation could increase operating costs for healthcare providers and intensify calls for regulatory intervention on drug pricing. The article highlights that despite the drops, these movements could present buying opportunities for high-quality stocks.
Addus HomeCare (NasdaqGS:ADUS) Stock Forecast & Analyst Predictions
Addus HomeCare (ADUS) is projected to grow earnings and revenue by 11.1% and 4.9% annually, respectively, with EPS expected to increase by 10.6% per year and ROE forecast at 10.6% in three years. Recent updates include a Q1 2026 revenue growth of 7.7% driven by organic growth and Indiana acquisitions, with EPS and revenue meeting analyst expectations. However, analysts have shown a cautious outlook due to updated models and potential regulatory risks from the Medicaid Access Rule, leading to some price target adjustments.
What Addus HomeCare (ADUS)'s Indiana-Fueled Q1 Profit Gains Mean For Shareholders
Addus HomeCare reported strong first-quarter 2026 results, with net income rising to US$25.07 million and diluted EPS reaching US$1.36, primarily driven by growth in Personal Care and Hospice segments aided by state rate increases and Indiana acquisitions. While this reinforces the company's core strategy, a 7% decline in Home Health revenue poses a near-term risk. The company continues to pursue acquisition-led expansion, but investors should be aware of rising labor costs and caregiver shortages as potential ongoing challenges.
Addus HomeCare Corp stock (US0067391062): Expansion into Indiana via HomeCourt acquisition
Addus HomeCare Corp is expanding its operations into Indiana through the acquisition of HomeCourt Home Care, a move that broadens its geographic footprint for home health and personal care services. This acquisition aligns with Addus's strategy to capitalize on aging demographics and demand for in-home care, diversifying its payer and referral base. While offering growth opportunities, investors should consider risks such as regulatory changes and integration challenges.
Is Addus HomeCare Corporation (ADUS) One of The Best Small Cap Value Stocks to Buy After Q1 ?
Addus HomeCare Corporation (NASDAQ: ADUS) is highlighted as a top small-cap value stock following its strong Q1 2026 results. The company reported a 7.7% increase in net service revenues and an increase in net income, driven by its personal care and hospice segments. Addus HomeCare is also expanding its footprint through strategic acquisitions.
Addus HomeCare (ADUS) Earnings Growth And 6.7% Margin Test Bullish Narratives
Addus HomeCare (ADUS) recently reported Q1 2026 results, showing 30.3% earnings growth and a 6.7% net margin. While this performance fuels a bullish outlook, with analyst targets and DCF fair value significantly above the current stock price, concerns remain due to more moderate forward growth expectations and potential policy risks affecting margins. The article discusses both bullish and bearish perspectives, highlighting the tension between strong historical earnings and future growth challenges.
Addus HomeCare Is Maintained at Market Outperform by Citizens
Citizens maintained its "Market Outperform" rating on Addus HomeCare. The article provides a detailed analyst report, outlining the company's performance and Citizens' continued positive outlook on its stock.
Addus HomeCare Corporation (NASDAQ:ADUS) Q1 2026 Earnings Call Transcript
Addus HomeCare Corporation (NASDAQ:ADUS) reported a strong first quarter for 2026, with total revenue increasing by 7.7% to $363.6 million and adjusted EPS rising by 14.1% to $1.62. The company's Personal Care segment drove growth with an 8.8% revenue increase, supported by recent acquisitions and rate increases in key states. Addus also announced strategic acquisitions in Indiana to expand its market reach and is optimistic about future growth and M&A opportunities, particularly as the home health regulatory environment appears to be stabilizing.
Addus HomeCare (ADUS) Earnings Growth And 6.7% Margin Test Bullish Narratives
Addus HomeCare (ADUS) recently reported strong Q1 2026 results with 30.3% earnings growth and a 6.7% net margin. While this fuels a bullish case, forward growth expectations for revenue and earnings are more moderate, creating tension for investors. The article explores both bullish perspectives, which envision higher margins and revenue, and bearish concerns regarding policy changes and cost pressures that could impact future profitability.
Addus HomeCare Q1 2026 Earnings Call: Complete Transcript
Addus HomeCare reported strong first-quarter 2026 results with a 7.7% revenue increase to $363.6 million and a 14.1% rise in adjusted EPS to $1.62. The company highlighted strategic acquisitions, including entering the Indiana market, and reduced its bank debt to $94.3 million with $103 million cash on hand, providing significant financial flexibility. Operational segments, particularly personal and hospice care, showed positive growth trends, supported by favorable regulatory developments and improved hiring.
Citizens cuts Addus HomeCare stock price target on revenue miss
Citizens has lowered its price target for Addus HomeCare (NASDAQ:ADUS) to $142 from $150, despite maintaining a Market Outperform rating, following mixed first-quarter 2026 results. While the company's consolidated revenue of $363.6 million exceeded Citizens' estimate, it fell short of consensus, and hospice revenue was lower than projected. However, adjusted EBITDA topped consensus estimates, and the stock is considered undervalued with a "GREAT" financial health score.
Earnings call transcript: Addus HomeCare beats EPS in Q1 2026, stock dips
Addus HomeCare (ADUS) reported Q1 2026 EPS of $1.62, exceeding analyst expectations of $1.55, but revenue of $363.6 million fell slightly short of forecasts. Despite the EPS beat and strong operational performance, including a 14.1% year-over-year EPS increase and 9.7% adjusted EBITDA growth, the stock dipped 3.12% in premarket trading due to the revenue miss. The company highlighted strong cash flow, debt reduction, and strategic acquisitions in new markets like Indiana, projecting continued growth and emphasizing its focus on integrated home-based care.
Addus HomeCare Earnings Call Highlights Profitable Growth
Addus HomeCare Corporation (ADUS) reported a strong Q1 2026, driven by accelerated revenue growth in Personal Care and Hospice segments and improved profitability. The company saw a 7.7% increase in revenue to $363.6 million and a 14.1% rise in adjusted EPS to $1.62, while also strengthening its balance sheet with surging operating cash flow. Despite minor setbacks like a temporary weather event and a decline in the Home Health segment, Addus remains confident in its ability to deliver continued profitable growth through strategic M&A and ongoing operational efficiencies.
Addus HomeCare (NASDAQ: ADUS) grows Q1 2026 profit and cash flow
Addus HomeCare (NASDAQ: ADUS) reported strong financial results for Q1 2026, with net service revenues increasing by 7.7% to $363.6 million and net income rising to $25.1 million. This growth was primarily driven by its personal care and hospice segments, while home health revenue saw a slight decline but improved margins. The company also demonstrated strengthened operating cash flow of $52.4 million, reduced debt, and continued strategic acquisitions to expand its personal care footprint.
Addus Enters Indiana With HomeCourt Acquisition, Lines Up Second Deal
Addus HomeCare Corporation has acquired Indiana-based HomeCourt Home Care, marking its entry into a new state, and has plans for a second acquisition of a similar-sized personal care provider in Indiana. This expansion aligns with Addus's strategy to enter attractive markets and leverage state rate increases, which are expected to boost annualized revenues by $17.5 million. The company is open to future larger transactions and home health acquisitions, while also navigating regulatory changes like the 80/20 rule and CMS's evolving stance on reimbursement.
Earnings call transcript: Addus HomeCare beats EPS in Q1 2026, stock dips
Addus HomeCare (ADUS) reported Q1 2026 EPS of $1.62, exceeding analyst expectations, but revenue of $363.6 million fell slightly short, causing the stock to dip 3.12% in premarket trading. The company highlighted strong cash flow, debt reduction, and growth in its personal care and hospice segments, while addressing investor concerns about revenue and regulatory aspects of self-directed care. Management also discussed M&A opportunities and positive hiring trends, projecting continued growth despite market volatility.
Addus HomeCare to Participate in Upcoming Investor Conferences in May
Addus HomeCare Corporation (Nasdaq: ADUS) announced its participation in two investor conferences in May: the BofA Securities 2026 Health Care Conference on May 12, 2026, and the RBC Capital Markets 2026 Global Healthcare Conference on May 19, 2026. Company executives, including the Chairman and CEO, President and COO, and Executive Vice President and CFO, will present at these events. Live broadcasts and replays of the presentations will be available on the company's website.
Addus HomeCare price target lowered to $140 from $147 at BofA
BofA has reduced its price target for Addus HomeCare (ADUS) to $140 from $147, while maintaining a Buy rating on the shares. This adjustment follows the company's Q1 report, with the firm keeping its EBITDA estimate but applying a lower multiple due to reduced peer group multiples. The update was initially published by TheFly.
Addus HomeCare Releases Q1 2026 Financial Results
Addus HomeCare Corporation reported first-quarter 2026 financial results that exceeded Wall Street expectations, driven by strong demand for in-home care services. The company posted adjusted earnings of $1.62 per share on revenue of $363.6 million, with its Personal Care segment showing significant year-over-year growth. Analysts maintain a largely positive outlook on the stock, citing the company's crucial role in healthcare cost-reduction efforts.
Addus HomeCare: Q1 Earnings Snapshot
Addus HomeCare Corp. (ADUS) reported first-quarter earnings of $25.1 million, or $1.36 per share, which adjusted to $1.62 per share, exceeding analyst expectations of $1.52. Despite beating profit forecasts, the company's revenue of $363.6 million missed Street estimates of $364.9 million. Addus HomeCare shares have seen a nearly 7% decrease year-to-date and almost a 5% drop over the last 12 months.
Earnings Flash (ADUS) Addus HomeCare Corporation Posts Q1 Adjusted EPS $1.62 per Share, Vs. FactSet Est of $1.54
Addus HomeCare Corporation (ADUS) announced its Q1 adjusted EPS of $1.62 per share, surpassing the FactSet estimate of $1.54. This release is an "Earnings Flash" indicating a quick dissemination of key financial results.
Addus HomeCare Corporation (ADUS) Stock Falls on Q1 2026 Earnings
Addus HomeCare Corporation (ADUS) reported mixed Q1 2026 results, with revenue growing 7.7% to $363.6 million and diluted EPS up 17.2% to $1.36. However, the company missed consensus estimates for both revenue ($373.5 million) and EPS ($1.58), leading to a 3.5% drop in stock price. Insider trading shows 30 sales and no purchases in the last six months, while institutional activity saw both significant additions and removals of shares.
Addus HomeCare (NASDAQ: ADUS) posts Q1 2026 growth and Indiana deal
Addus HomeCare (NASDAQ: ADUS) reported strong financial results for Q1 2026, with net service revenues increasing by 7.7% to $363.6 million and adjusted EBITDA rising by 9.7% to $44.5 million. The growth was primarily driven by its personal care and hospice segments, benefiting from higher volumes and rate adjustments in key states. Additionally, Addus expanded its market presence by acquiring HomeCourt Home Care in Indiana and signing an agreement for another similar acquisition in the state, reinforcing its strategy of increasing density in targeted markets.
Earnings Flash (ADUS) Addus HomeCare Corporation Reports Q1 Revenue $363.6M, Vs. FactSet Est of $366.4M
Addus HomeCare Corporation (ADUS) announced its Q1 revenue reached $363.6 million, falling slightly short of the FactSet estimate of $366.4 million. This earnings flash provides key financial data for the company's performance in the first quarter.
Earnings Flash (ADUS) Addus HomeCare Corporation Reports Q1 Revenue $363.6M, vs. FactSet Est of $366.4M
Addus HomeCare Corporation reported Q1 revenue of $363.6 million, falling short of the FactSet estimate of $366.4 million. The article provides a brief overview of the company's financial performance for the first quarter and shares recent news and analyst consensus.
Addus HomeCare Announces First Quarter 2026 Financial Results
Addus HomeCare Corporation announced strong financial results for the first quarter of 2026, with net service revenues increasing by 7.7% to $363.6 million and adjusted EBITDA up 9.7%. The company also expanded its market reach with the acquisition of HomeCourt Home Care's personal care operations in Indiana and plans for further expansion in the state. These results highlight continued demand for home-based care services and the effectiveness of their growth strategy.
Addus HomeCare: Q1 Earnings Snapshot
Addus HomeCare Corp. (ADUS) reported first-quarter earnings of $25.1 million, or $1.36 per share, with adjusted earnings of $1.62 per share, surpassing Wall Street's expectation of $1.52 per share. Despite exceeding profit forecasts, the company's revenue of $363.6 million missed analyst estimates of $364.9 million. Addus HomeCare shares have seen a nearly 7% decrease year-to-date and almost 5% over the last 12 months.
Addus HomeCare (NASDAQ:ADUS) Misses Q1 CY2026 Sales Expectations
Addus HomeCare (NASDAQ: ADUS) reported its Q1 CY2026 earnings, missing Wall Street's revenue expectations despite a 7.7% year-on-year sales increase to $363.6 million. However, the company surpassed analyst estimates for non-GAAP profit, reaching $1.62 per share. Despite the revenue miss, Addus HomeCare demonstrated solid long-term sales growth and improved profitability.
Addus earnings set to test growth momentum after Gentiva deal
Addus HomeCare Corporation is expected to report its first-quarter earnings on Monday, with analysts predicting growth despite sequential declines from the previous quarter. The company's ability to maintain margin discipline, manage its recent acquisition of Gentiva's personal care operations, and navigate workforce shortages and reimbursement trends will be key focuses for investors. Wall Street sentiment remains positive, with a majority of analysts rating the stock as a Buy.
At US$99.56, Is It Time To Put Addus HomeCare Corporation (NASDAQ:ADUS) On Your Watch List?
Addus HomeCare Corporation's stock (NASDAQ:ADUS) has seen recent price fluctuations, and is currently trading at US$99.56. The company appears undervalued based on its P/E ratio compared to the industry average, and analysts project a 42% growth in earnings over the next few years. This optimistic outlook, not yet fully reflected in the share price, suggests a potential buying opportunity for investors.
Addus HomeCare (ADUS) Projected to Post Quarterly Earnings on Monday
Addus HomeCare (ADUS) is expected to report its Q1 2026 earnings on Monday, May 4th, with analysts projecting $1.55 EPS and $366.36 million in revenue. The company maintains an average analyst rating of "Moderate Buy" with a target price of $133.22, despite recent insider share sales. Institutional investors hold a significant majority stake in the company.
ADUS Price Today: Addus HomeCare Corp. Stock Price, Quote & Chart | MEXC
Addus HomeCare Corp. (ADUS) is currently trading at $97.25, up 2.12% from its previous close. The company provides in-home care services across three segments: Personal Care, Hospice, and Home Health. Over the past year, ADUS has shown a "Weak" performance with a -3.75% price change, reflecting its classification within the SERVICES-HOME HEALTH CARE SERVICES sector on NASDAQ.
Addus HomeCare (NASDAQ: ADUS) details 2026 proxy votes and pay
Addus HomeCare Corporation is preparing for its 2026 virtual annual shareholder meeting on June 10, 2026, where shareholders will vote on electing two Class II directors, ratifying PricewaterhouseCoopers LLP as independent auditor, and approving executive officer compensation on an advisory basis. The proxy statement details the company's governance structure, ESG priorities, and an executive pay program that links annual bonuses and equity awards to Adjusted EBITDA performance. Key financial figures for 2025 related to executive compensation, including an Adjusted EBITDA target of $174,548,000 and an achieved $181,849,000, are also presented.
Addus HomeCare (ADUS) Proxy filing Summary
Addus HomeCare (ADUS) shareholders will convene virtually on June 10, 2026, to vote on director elections, auditor ratification, and executive compensation. The board recommends approval for all proposals, including the election of two Class II directors and the ratification of PricewaterhouseCoopers LLP. With 18,664,776 shares outstanding as of April 23, 2026, voting can be done online, by phone, or mail, and a replay will be available.
Addus HomeCare (ADUS) Investor presentation Summary
Addus HomeCare (ADUS) operates in 23 states, providing personal care, hospice, and home health services, primarily to the elderly. The company achieved $1.4 billion in revenues in 2025 with strong financial stability, including consistent gross margins and growing earnings per share. Addus HomeCare plans to continue growth through organic strategies and accretive acquisitions, such as the recent Gentiva personal care operations acquisition, enhancing its service offerings and geographic reach.
